San Diego – March 30, 2015 – Cooley advised Horizon Pharma Public Limited Company and Horizon Pharma Investments Limited on the Rule 144A offering of $400 million aggregate principal amount of exchangeable senior notes due 2022. The sale of the notes included the initial purchasers' exercise in full of their option to purchase an additional $50 million aggregate principal amount of notes.

Horizon is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs.

About Cooley LLP

Cooley's lawyers solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, often where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.